Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195874 | 1.00 | TSHR (0.42) | TSHRSLC5A2TLR9GBA1TDP1 | |
| SCHEMBL8310780 | 1.00 | TSHR (0.42) | TSHRSLC5A2TLR9GBA1TDP1 | |
| SCHEMBL5195871 | 1.00 | TSHR (0.42) | TSHRSLC5A2TLR9GBA1TDP1 | |
| SCHEMBL31231840 | 0.89 | TLR9 (0.47) | TSHRTLR9GBA1SLC6A2SLC6A4 | |
| SCHEMBL12459457 | 0.86 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL12582923 | 0.86 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL7147747 | 0.86 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL13446904 | 0.84 | SLC5A2 (0.55) | SLC5A2 | |
| SCHEMBL7173273 | 0.83 | TLR9 (0.42) | TSHRSLC5A2TLR9GBA1TDP1 | |
| SCHEMBL12582958 | 0.80 | SLC5A2 (0.44) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0987595-B1 | Method of making hydroxy-substituted hydroxylamines and color developers containing same | EASTMAN KODAK CO (US) | 2004-06-16 | — | — | EP | claimed |
| EP-0987595-A1 | Method of making hydroxy-substituted hydroxylamines and color developers containing same | EASTMAN KODAK COMPANY (US) | 2000-03-22 | — | — | EP | claimed |
| US-6028225-A | REACTING HYDROXYLAMINE OR A MONO-SUBSTITUTED HYDROXYLAMINE, IN FREE BASE FORM, WITH AN EPOXIDE; CAN BE USED WITHOUT ISOLATION FROM THE REACTION SOLUTION, COMBINED WITH A COLOR DEVELOPING AGENT; ODORLESS, BY-PRODUCT INHIBITION | EASTMAN KODAK COMPANY (US) | 2000-02-22 | — | — | US | claimed |
| US-5709982-A | MIXTURE OF A HYDROXYLAMINE AND EPOXIDE | EASTMAN KODAK COMPANY (US) | 1998-01-20 | — | — | US | claimed |
| US-5620835-A | MIXTURE OF AN HYDROXYLAMINE AND EPOXIDE | EASTMAN KODAK COMPANY (US) | 1997-04-15 | — | — | US | claimed |
| US-5508155-A | WATER SOLUBLE | EASTMAN KODAK COMPANY (US) | 1996-04-16 | — | — | US | claimed |
| US-9889115-B2 | Fitness assay and associated methods | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2336134-B1 | Fitness assay and methods for reducing resistance of HIV to therapy | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-31 | — | — | EP | disclosed |
| CN-102844385-B | The surface treatment of cement matrix | WACKER CHEMIE AG (DE) | 2016-01-20 | — | — | CN | disclosed |
| US-9233943-B2 | Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | disclosed |
| EP-1088098-B2 | FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20150011782-A1 | PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-01-09 | — | — | US | disclosed |
| WO-1997042180-A1 | PROCESS FOR PREPARING OXIRANEMETHANAMINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| US-5620835-A | MIXTURE OF AN HYDROXYLAMINE AND EPOXIDE | EASTMAN KODAK COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| US-5508155-A | WATER SOLUBLE | EASTMAN KODAK COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5277895-A | Nuclear magnetic resonance | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-11 | — | — | US | disclosed |
| EP-0485045-A2 | Mono-N-substituted 1,4,7,10-Tetraazacyclododecan-derivatives, process for their preparation and pharmaceutical agent containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-05-13 | — | — | EP | disclosed |
| US-5084582-A | Ruthenium catalyst for oxidation of alcohols to acids | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1992-01-28 | — | — | US | disclosed |
| EP-0362628-A2 | 6-Membered lactones and process for their production | Takano, Seiichi (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | CPS1, CTSS, TST | TSHR 3041/4885SLC5A2 2171/4885TLR9 4208/4885 |
| US-20150011782-A1 | PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR | POR, CYP3A4, CYP2S1 | TSHR 3483/4885SLC5A2 3749/4885TLR9 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.